肝癌、肺癌、胃癌患者血清GST-π含量的测定及其临床意义  

Determination of Serum GST-π in Patients with hepatoma, Lung and Gastric Carcinomas and Its Clinical signification

作　　者：金贵善[1] 徐明旭[1] 柳明洙[1] 尹宗柱[1] 朴龙根[2] 

机构地区：[1]延边医学院生化教研室 [2]延边肿瘤医院

出　　处：《延边医学院学报》1992年第2期87-90,共4页Journal of Medical Science Yanbian University

基　　金：国家卫生部重点科研基金

摘　　要：采用Guesdon法制备出生物素化兔抗人GST-π抗体(B-IgG)。以生物素-亲和素-酶联免疫吸附试验(BA-ELISA)测定了肝癌、肺癌、胃癌患者血清和胎儿脐带血血清中的GST-π含量。测定结果,肝癌、肺癌、胃癌患者血清中GST-π含量分别为7.25±6.47ng/ml,4.3±1.85ng/ml,3.74±2.25ng/ml,比正常人的1.16+0.81ng/ml均显著升高,胎儿脐带血血清中GST-π含量为1.14±0.88ng/ml,与正常人相比无明显差异。故认为,血清中GST-π很有可能成为肝癌、肺癌、胃癌的一个肿瘤标志。The Biotin-labeled anti-GST-π antibody was obtained by a procedure described by Guesdon et al. The GST-π in serum was determined using biotin-avidin enzyme-linked immunosorbent ashy. The serum GST-π concentrations were 7.25±4-6.47ng/ml, 4.3±1.85ng/ml, 3.74±2.25ng/ml in patients with hepatoma, lung and gastric carcinomas, respectivily, they were all significantly higher than normal controls (1.16±0.81 ng/ml). The results appear that the serum GST-π contents might be a tumor marker for the patients with these carcinomas. The serum GST-π of fetal umbilical cord was also determined (1.14±0.88ng/ml), showing no difference compared with normal controls.

关 键 词：谷胱甘肽 转移酶 肝肿瘤 肺肿瘤 

分 类 号：R730.231.3[医药卫生—肿瘤]